Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

NCT03703297 PHASE3 ACTIVE_NOT_RECRUITING Results posted

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Details

Lead sponsor	AstraZeneca
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	730
Start date	Thu Sep 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Small Cell Lung Cancer

Interventions

• Durvalumab
• Tremelimumab
• Placebo

Countries

Italy, Japan, Taiwan, Vietnam, Poland, South Korea, Netherlands, Russia, Belgium, Czechia, United States, Argentina, Canada, Spain, United Kingdom, Germany, China, Turkey (Türkiye), India